Recent Finacing
Recent Raise
Purespring Therapeutics develops adeno-associated viral (AAV) gene therapies that directly target podocytes for IgA nephropathy, complement-mediated kidney diseases, nephrotic syndrome, and other glomerular disorders, advancing PS-002 to Phase I/II.
